Evidence map›Paper›PMID 36514501›Full record

ArticleJGH open : an open access journal of gastroenterology and hepatology2022

Clinicopathological characteristics of advanced gastric cancer after

Junki Tokura, Ken Namikawa, Kaoru Nakano, Yoshitaka Tokai, Shoichi Yoshimizu, Yusuke Horiuchi, Akiyoshi Ishiyama, Toshiyuki Yoshio, Toshiaki Hirasawa, Souya Nunobe and 3 more

Open access · goldAbstract read
In one paragraph

Article in JGH open : an open access journal of gastroenterology and hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. [Approach to Patients after Successful Eradication ofThe Korean journal of helicobacter and upper gastrointestinal research · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Junki TokuraDepartment of Gastroenterology Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan.ORCID https://orcid.org/0000-0002-5242-0192
Ken NamikawaDepartment of Gastroenterology Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan.
Kaoru NakanoDepartment of Pathology Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan.
Yoshitaka TokaiDepartment of Gastroenterology Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan.ORCID https://orcid.org/0000-0002-3370-4405
Shoichi YoshimizuDepartment of Gastroenterology Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan.
Yusuke HoriuchiDepartment of Gastroenterology Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan.ORCID https://orcid.org/0000-0001-8116-8152
Akiyoshi IshiyamaDepartment of Gastroenterology Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan.ORCID https://orcid.org/0000-0002-7626-645X
Toshiyuki YoshioDepartment of Gastroenterology Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan.ORCID https://orcid.org/0000-0002-6546-0329
Toshiaki HirasawaDepartment of Gastroenterology Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan.
Souya NunobeDepartment of Gastroenterological Surgery Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan.
Kensei YamaguchiDepartment of Gastroenterology Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan.
Hiroshi KawachiDepartment of Pathology Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan.
Junko FujisakiDepartment of Gastroenterology Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan.
Japanese Foundation For Cancer Research · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aim: Methods: This single-center, retrospective study included 261 consecutive patients diagnosed with AGC through EGD. The patients were grouped based on their Results: The radical resection (R0) rate was higher in the eradication group. In surgical cases, the median tumor diameter was shorter in the eradication group. Analysis of EGD surveillance after eradication in 36 available cases showed that 24 (66.7%) were detected within 5 years after eradication, and 3 (8.3%) were diagnosed as AGC > 20 years after eradication. The R0 rates in the short-, intermediate-, and long-interval groups were 83.3%, 71.4%, and 60%, respectively. Conclusions: AGC after eradication was more often detected at the phase in which R0 resection was possible. EGD follow-up with tight intervals of at least 5 years after eradication is advisable.

Indexed as

advanced gastric cancerendoscopic surveillanceeradicationHelicobacter pylori

Identifiers

PMID36514501
PMCPMC9730718
OpenAlexW4307984965

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.